🚨 Medical News - Failed Trials and New Approvals
Novartis's pelacarsen, a monthly shot to lower lipoprotein(a), failed its Phase 3 outcomes trial. The trial involved 8,323 patients with established heart disease and high Lp(a). The failure of this trial may impact the treatment options for patients with high Lp(a) levels.
Key Points:
• Novartis's pelacarsen failed its Phase 3 outcomes trial.
• The trial involved 8,323 patients with established heart disease and high Lp(a).
• The failure of this trial may impact the treatment options for patients with high Lp(a) levels.
🔗 Resources:
• https://x.com/houmanhemmati/status/2096016849112793148 ↗ - Original post
• Novartis ↗ - Pharmaceutical company
🚀 Medical News - KOL Reactions to ETCAMAH Approval
KOL Pulse Virtual Medical Science Liaison (MSL) reviewed the early KOL reactions to the ETCAMAH (camizestrant) @FDA approval based on the SERENA-6 trial regimen for ESR1-mutated advanced breast cancer.
Key Points:
• KOL Reactions from @ErikaHamilton9 and @NeilVasan (acting chair of the April Oncologic Drugs Advisory Committee) were reviewed.
• The KOL reactions highlighted the potential benefits of ETCAMAH in treating ESR1-mutated advanced breast cancer.
• The approval of ETCAMAH represents a major shift toward adaptive cancer management and earlier interception of disease progression based on a blood test.
🔗 Resources:
• https://x.com/KolPulseAI/status/2096077485683130371 ↗ - Original post
• KOL Pulse AI ↗ - Medical Science Liaison
🤖 Medical News - Voice Disorders and Cognitive Impairment
A study of 833,417 patients found that voice disorders without hearing loss were linked to a 58% higher risk of cognitive impairment or dementia.
Key Points:
• The study found a link between voice disorders and cognitive impairment or dementia.
• The risk of cognitive impairment or dementia was 58% higher in patients with voice disorders.
• The study highlights the importance of addressing voice disorders in patients with cognitive impairment or dementia.
🔗 Resources:
• https://x.com/medical_xpress/status/2096056852094103626 ↗ - Original post
• Medical Xpress ↗ - Science news website
🚨 Medical News - Adagrasib + Cetuximab Withdrawal
The FDA withdrew the accelerated approval for adagrasib + cetuximab in KRAS G12C colorectal cancer after the KRYSTAL-10 trial failed to confirm benefit.
Key Points:
• The FDA withdrew the accelerated approval for adagrasib + cetuximab.
• The KRYSTAL-10 trial failed to confirm the benefit of adagrasib + cetuximab in KRAS G12C colorectal cancer.
• The withdrawal of this approval may impact the treatment options for patients with KRAS G12C colorectal cancer.
🔗 Resources:
• https://x.com/GIMedOnc/status/2096040363542634808 ↗ - Original post
• GIMedOnc ↗ - Medical oncology expert
🚀 Medical News - Cancer Drug Slows Plaque Growth
A cancer drug slowed plaque growth and reduced vulnerable plaque in animal models of atherosclerosis by blocking PRC2, a protein complex tied to disturbed blood flow and arterial inflammation.
Key Points:
• The cancer drug slowed plaque growth and reduced vulnerable plaque in animal models of atherosclerosis.
• The drug blocked PRC2, a protein complex tied to disturbed blood flow and arterial inflammation.
• The study highlights the potential benefits of targeting PRC2 in the treatment of atherosclerosis.
🔗 Resources:
• https://x.com/medical_xpress/status/2096026593638429108 ↗ - Original post
• Medical Xpress ↗ - Science news website
🚨 Medical News - Etentamig Positive Topline Results
AbbVie announced positive topline results from the Phase 3 CERVINO trial showing etentamig significantly improved outcomes in patients with a specific type of cancer.
Key Points:
• AbbVie announced positive topline results from the Phase 3 CERVINO trial.
• The trial showed that etentamig significantly improved outcomes in patients with a specific type of cancer.
• The results of this trial may impact the treatment options for patients with this type of cancer.
🔗 Resources:
• https://x.com/IMFjimMYELOMA/status/2096021696037704144 ↗ - Original post
• IMFjimMYELOMA ↗ - Medical oncology expert
🚀 Medical News - WCLC26 Preparation
In this episode of Lung Cancer Considered, the hosts discuss what to expect at the upcoming WCLC26 conference.
Key Points:
• The hosts discussed what to expect at the upcoming WCLC26 conference.
• The conference will feature presentations on the latest research and advancements in lung cancer treatment.
• The hosts provided tips for attendees on how to make the most of the conference.
🔗 Resources:
• https://x.com/NarjustFlorezMD/status/2095972804336234512 ↗ - Original post
• NarjustFlorezMD ↗ - Pulmonologist
🚨 Medical News - Camizestrant Approval
The FDA granted accelerated approval for camizestrant based on the SERENA-6 trial regimen for ESR1-mutated advanced breast cancer.
Key Points:
• The FDA granted accelerated approval for camizestrant.
• The approval was based on the SERENA-6 trial regimen for ESR1-mutated advanced breast cancer.
• The approval represents a major shift toward adaptive cancer management and earlier interception of disease progression based on a blood test.
🔗 Resources:
• https://x.com/NeilVasan/status/2096013826948759668 ↗ - Original post
• NeilVasan ↗ - Medical oncology expert
🚀 Medical News - Guardant360 CDx Approval
The FDA approved Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant) in advanced breast cancer.
Key Points:
• The FDA approved Guardant360 CDx as a companion diagnostic.
• The approval was for use with AstraZeneca's ETCAMAH (camizestrant) in advanced breast cancer.
• The approval represents a major shift toward adaptive cancer management and earlier interception of disease progression based on a blood test.
🔗 Resources:
• https://x.com/GuardantHealth/status/2096010607724007714 ↗ - Original post
• Guardant Health ↗ - Companion diagnostic company
🎙️ Medical News - SERENA6 Strategy
In this podcast episode, the hosts discuss the SERENA6 strategy for treating ESR1-mutated advanced breast cancer.
Key Points:
• The hosts discussed the SERENA6 strategy for treating ESR1-mutated advanced breast cancer.
• The strategy involves using a blood test to detect molecular resistance and adapt treatment accordingly.
• The hosts highlighted the potential benefits of this approach in improving patient outcomes.
🔗 Resources:
• https://x.com/PTarantinoMD/status/2096003385505821149 ↗ - Original post
• PTarantinoMD ↗ - Medical oncology expert
